Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons

Behavioural Pharmacology

Volumn 9, Issue 3, 1998, Pages 285-297

  Weerts, E M ^a   Griffiths, R R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Baboon; Benzodiazepines; Drug abuse; Feeding; Flumazenil; Physical dependence; Reinforcement; Self administration; Withdrawal

Indexed keywords

FLUMAZENIL; ZOLPIDEM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; INTRAVENOUS DRUG ABUSE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; FLUMAZENIL; FOOD; GABA MODULATORS; HYPNOTICS AND SEDATIVES; INJECTIONS, INTRAVENOUS; MALE; PAPIO; PYRIDINES; SELF ADMINISTRATION; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 0031776802     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Ator NA, Griffiths RR (1987). Self-administration of barbiturates and benzodiazepines: A review. Pharmacol, Biochem Behav 27:391-398.
2. Ator NA, Griffiths RR (1992). Differential discriminative-stimulus effects of anxiolytics and hypnotics in rats trained to discriminate lorazepam (LRZ), diazepam (DZP), or pentobarbital (PB). Soc Neurosci Abstr 18:1158.
3. Ator NA, Kaminski BJ, Kautz MA, Weerts EM, Griffiths RR (1996). Triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen. In Harris LS, editor. Problems of drug dependence, 1995. NIDA Research Monograph No. 162. NIH Publication No. 96-4116. Washington, DC: US Government Printing Office, p. 248.
4. 1) subtype. J Pharmacol Exp Ther 245:1033-1041.
5. 3H] flumazenil binding in the rat central nervous system. J Pharmacol Exp Ther 263:884-896.
6. Biggio G, Concas A, Corda MG, Serra M (1989). Enhancement of GABAergic transmission by zolpidem, an imidazopyridine with preferential affinity for type I benzodiazepine receptors. Eur J Pharmacol 161:173-180.
7. Bottlender R, Schütz C, Möller H-J, Soyka M (1997). Zolpidem dependence in a patient with former polysubstance abuse. Pharmacopsychiatry 30:108.
8. Cavallaro R, Regazzetti MG, Covelli G, Smeraldi E (1993). Tolerance and withdrawal with zolpidem. Lancet 342:374-375.
9. Cohen C, Sanger DJ (1994). Tolerance, cross tolerance and dependence measured by operant responding in rats treated with triazolam via osmotic pumps. Psychopharmacology 115:86-94.
10. Cooper SJ (1991). Benzodiazepines, appetite and stress. In Simon P, Soubrie P, Wildlocher D, editors. Animal models of psychiatric disorders. Basel: S. Karger. pp. 24-44.
11. Cooper SJ, Desa A (1988). Pyrazoloquinolines and zolpidem: effects on hypertonic saline consumption in rehydrating rats. Drug Dev Res 14:161-168.
12. Cooper SJ, Francis RL (1979). Feeding parameters with two food textures after chlordiazepoxide administration, alone or in combination with d-amphetamine or fenfluramine. Psychopharmacology 62:253-259.
13. Cooper SJ, Moores WR (1985). Chlordiazepoxide-induced hyperphagia in non-food-deprived rats: effects of Ro15-1788, CGS 8215 and ZK 93426. Eur J Pharmacol 112:39-45.
14. Cooper SJ, Yerbury RE, Neill JC, Desa A (1987). Partial agonists acting at benzodiazepine receptors can be differentiated in tests of ingestional behavior. Physiol Behav 41:247-255.
15. Cox A, Boyland P, Gent JP, Feely M (1988). Investigation of anticonvulsant tolerance to zolpidem in mice. Br J Pharmacol 95:667P.
16. Deneau G, Yanagita T, Seevers MH (1969). Self-administration of psychoactive substances by the monkey - a measure of psychological dependence. Psychopharmacologia (Berl.). 16:30-48.
17. Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, et al. (1986). Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237:649-658.
18. Durand A, Thénot JP, Bianchetti G, Morselli PL (1992). Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab Rev 24:239-266.
19. Evans SM, Funderburk FR, Griffiths RR (1990). Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 255:1246-1255.
20. Foltin RW, Fischman MW, Byrne MF (1989). Food intake in baboons: effects of diazepam. Psychopharmacology 97:443-447.
21. Griffiths RR, Mumford GK (1995). Caffeine - a drug of abuse? In Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. pp. 1699-1713.
22. Griffiths RR, Weerts EM (1997). Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. Psychopharmacology 134:1-37.
23. Griffiths RR, Winger G, Brady JV, Snell JD (1976). Comparison of behavior maintained by infusions of eight phenylethylamines in baboons. Psychopharmacology 50:251-258.
24. Griffiths RR, Bigelow GE, Henningfield JE (1980). Similarities in animals and human drug-taking behavior. In Mello NK, editor. Advances in substance abuse. Vol. I. Greenwich, CT: JAI Press, pp. 1-90.
25. Griffiths RR, Lukas SE, Bradford LD, Brady JV, Snell J (1981). Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology 75:101-109.
26. Griffiths RR, Lamb RJ, Sannerud CA, Ator NA, Brady JV (1991). Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. Psychopharmacology 103:154-161.
27. Griffiths RR, Sannerud CA, Ator NA, Brady JV (1992). Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther 260:1199-1208.
28. Johanson CE, Balster RL, Bonese K (1976). Self-administration of psychomotor stimulant drugs: the effects of unlimited access. Pharmacol, Biochem Behav 4:45-51.
29. Kaminski BJ, Sannerud CA, Griffiths RR (1993). Sedative/ myorelaxant and physical dependence-producing effects of zolpidem in baboons. In Harris LS, editor. Problems of drug dependence, 1992, NIDA Research Monograph No. 132. NIH Publication No. 93-3505. Washington, DC: US Government Printing Office. p. 238.
30. Kubota A, Kuwahara A, Hakkei M, Nakamura K (1986). Drug dependence test on a new anesthesia inducer, midazolam. Folia Pharmacol Jap 88:125-158.
31. Lamb RJ, Griffiths RR (1987). Effects of Ro 15-1788 and CGS 8216 in diazepam-dependent baboons. Eur J Pharmacol 143:205-212.
32. Langer SZ, Arbilla S (1988). Imidazopyridines as a tool for characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes. Pharmacol, Biochem Behav 29:763-766.
33. Langtry HD, Benfield P (1990). Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40:291-313.
34. A receptor supramolecular complex: a consideration of the new ω1-receptor selective imidazopyridine hypnotic zolpidem. Pharmacol, Biochem Behav 29:781-783.
35. Lukas S E, Griffiths RR (1982). Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro15-1788). after 7 days of diazepam. Science 217:1161-1163.
36. Lukas SE, Griffiths RR (1984). Precipitated diazepam withdrawal in baboons: effects of dose and duration of diazepam exposure. Eur J Pharmacol 100:163-171.
37. Lukas SE, Griffiths RR, Bradford LD, Brady JV, Daley L, Delorenzo R (1982). A tethering system for intravenous and intragastric drug administration in the baboon. Pharmacol, Biochem Behav 17:823-829.
38. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL (1992). The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Intern Med Res 20:162-170.
39. Miczek KA (1982). Ethological analysis of drug action on aggression, defense and defeat. In Speigelstein MY, Levy A, editors. Behavioral models and analysis of drug action. Amsterdam: Elsevier. pp. 225-239.
40. Mintzer MZ, Frey JM, Yingling JE, Griffiths RR (1997). Triazdam and Zolpidem: a comparison of their psychomotor, cognitive and subjective effects in healthy volunteers. Behav Pharmacol 8:561-574.
41. Nader MA, Winger G, Woods JH, Woolverton WL (1991). Discriminative and reinforcing effects of brotizolam in rhesus monkeys. Psychopharmacology 103:166-171.
42. Naruse T (1994). Effects of repeated intravenous administration of diazepam on food intake in rats. Fund Clin Pharmacol 8:379-384.
43. Perrault G, Morel E, Sanger DJ, Zivkovic B (1990). Pharmacological profiles of four new hypnotics with different chemical structures: quazepam, brotizolam, zopiclone and zolpidem. Eur J Pharmacol 187:487-494.
44. Perrault G, Morel E, Sanger DJ, Zivkovic B (1992). Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 263:298-303.
45. Pickens RW, Thompson T (1968). Cocaine-reinforced behavior in rats: effects of reinforcement magnitude and fixed-ratio size. J Pharmacol Exp Ther 161:122-129.
46. Rowlett JK, Woolverton WL (1997). Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: I. Comparison with triazolam in rhesus monkeys and rats. J Pharmacol Exp Ther 280:162-173.
47. Rush CR, Griffiths RR (1996). Zolpidem, triazolam, and temazepam: behavioral and subject-rated effects in normal volunteers. J Clin Psychopharmacol 16:146-157.
48. Rush CR, Madakasira S, Goldman NH, Woolverton WL, Rowlett J K (1997). Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects:II. Comparison with triazolam and caffeine in humans. J Pharmacol Exp Ther 280:174-188.
49. Salva P, Costa J (1995). Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 29:142-153.
50. Sanger DJ, Zivkovic B (1986). The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic. Psychopharmacology 89:317-322.
51. Sanger DJ, Zivkovic B (1987). Investigation of the development of tolerance to the actions of zolpidem and midazolam. Neuropharmacology 26:1513-1518.
52. Sanger DJ, Zivkovic B (1988). Further behavioural evidence for the selective sedative action of zolpidem. Neuropharmacology 27:1125-1130.
53. Sanger DJ, Zivkovic B (1992). Differential development of tolerance to the depressant effects of benzodiazepine and non-benzodiazepine agonists at the omega (BZ) modulatory sites of GABAA receptors. Neuropharmacology 31:693-700.
54. Sanger DJ, Perrault G, Morel E, Joly D, Zivkovic B (1987). The behavioral profile of zolpidem, a novel hypnotic drug of imidazopyridine structure. Physiol Behav 41:235-240.
55. Sannerud CA, Allen M, Cook JM, Griffiths RR (1991). Behavioral effects of benzodiazepine ligands in non-dependent, diazepam-dependent and diazepam-withdrawn baboons. Eur J Pharmacol 202:159-169.
56. Schuster Jr CR (1970). Psychological approaches to opiate dependence and self-administration by laboratory animals. Fed Proc 29:2-5.
57. Stanhope KJ, Roe S, Dawson G, Draper F, Jackson A (1993). Effect of the benzodiazepine receptor agonist, zolpidem, on palatable fluid consumption in the rat. Psychopharmacology 111:185-189.
58. Stephens DN, Sanger DJ (1996). The abuse and dependence liabilities of zolpidem. In Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier. pp. 73-86.
59. Von Voightlander PF, Lewis RA (1991). A rapid screening method for the assessment of benzodiazepine receptor-related physical dependence in mice. J Pharmacol Methods 26:1-5.
60. Watsky E (1996). Management of zolpidem withdrawal. J Clin Psychopharmacol 16:459.
61. Weerts EM, Tornatzky W, Miczek KA (1993). 'Anxiolytic' and 'anxiogenic' benzodiazepines and beta-carbolines: effects on aggressive and social behavior in rats and squirrel monkeys. Psychopharmacology 110:451-459.
62. Weerts EM, Kaminski BJ, Griffiths RR (1998a). Stable low-rate midazolam self-injection with concurrent physical dependence under conditions of long-term continuous availabilty in baboons. Psychopharmacology 135:70-81.
63. Weerts EM, Ator NA, Grech DM, Griffiths RR (1998b). Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J Pharmacol Exp Ther (in press).
64. Wilson MC, Hitomi M, Schuster CR (1971). Psychomotor stimulant self administration as a function of dosage per injection in the rhesus monkey. Psychopharmacologia (Berl.) 22:271-281.
65. Winger G, Stitzer ML, Woods JH (1975). Barbiturate-reinforced responding in rhesus monkeys: comparisons of drugs with different durations of action. J Pharmacol Exp Ther 195:505-514.
66. Woods JH, Katz JL, Winger G (1987). Abuse liability of benzodiazepines. Pharmacol Rev 39:251-419.
67. Woods JH, Katz JL, Winger G (1992). Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 44:151-347.
68. Woolverton WL, Nader MA, Winger G, Woods JH, Patrick GA, Harris LS (1993). Progress report from the testing program for stimulant and depressant drug (1992). In Harris LS, editor. Problems of drug dependence, 1992. NIDA Research Monograph No. 132. NIH Publication No. 93-3505. Washington, DC: US Government Printing Office. pp. 579-594.
69. Yerbury RE, Cooper SJ (1989). Novel benzodiazepine receptor ligands: palatable food intake following zolpidem, CGS 17867A, or Ro23-0364, in the rat. Pharmacol. Biochem Behav 33:303-307.
70. Yokel RA, Pickens R (1974). Drug level of d- and l-amphetamine during intravenous self-administration. Psychopharmacologia (Berl.) 34:255-264.